FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 90 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 MOST POPULAR Man Who Lost His Mother to Breast Cancer Opens Resource Center... May 6, 2021 Celebrating 75 years of NHS cancer care July 5, 2023 Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 August 20, 2020 Prevention and Early Detection of Gastrointestinal Cancers Take on New Importance... June 27, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tislelizumab Strangers Buy Boy Stuffed Animals For His Birthday When His Mom... Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with... Skull Implant Delivers Drugs with Precision, Offering Hope for Parkinson’s, Cancer,...
